Profilo
Todd Saunders is currently the Vice President of Marketing at Osteal Therapeutics, Inc. since 2022.
He is also a Partner at Stanmore Medical Investments LLC since 2013.
Mr. Saunders has a graduate degree from Dartmouth College and undergraduate degrees from Dartmouth College and Bates College, with the latter being conferred in 2000.
Posizioni attive di Todd Saunders
| Società | Posizione | Inizio |
|---|---|---|
Stanmore Medical Investments LLC
Stanmore Medical Investments LLC Investment ManagersFinance Stanmore Medical Investments invests in companies located in the United States. The firm focuses on medical devices sector. It provides financing for early stage capital requirements with an investment size ranging from USD 1 - 3 million. | Investitore di Private Equity | 01/02/2013 |
Osteal Therapeutics, Inc.
Osteal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections | Presidente | 01/06/2022 |
Formazione di Todd Saunders
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bates College
Bates College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanmore Medical Investments LLC
Stanmore Medical Investments LLC Investment ManagersFinance Stanmore Medical Investments invests in companies located in the United States. The firm focuses on medical devices sector. It provides financing for early stage capital requirements with an investment size ranging from USD 1 - 3 million. | Finance |
Osteal Therapeutics, Inc.
Osteal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections | Health Technology |
















